AstraZeneca has scored another success with Tagrisso in Europe, by receiving an expanded marketing authorisation for Tagrisso in the first-line setting for patients with locally-advanced or metastatic non-small cell lung cancer, with activating epidermal growth factor receptor mutations.
The approval comes on the back of data from trials showed that Tagrisso was able to reduce risk of disease progression or death by 54% when compared against standard treatment.
Original Article: EU gives nod to expanded label for AZ’s Tagrisso